Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × veltuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 4 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 91 Rituximab 73 Peripheral Blood Stem Cell Transplantation 38 fludarabine phosphate 37 fludarabine 36 Filgrastim 32 Lenalidomide 31 Radiotherapy 28 Busulfan 28 Methotrexate 27 Etoposide 27 Cyclosporine 27 Melphalan 26 Cytarabine 26 venetoclax 25 Mycophenolic Acid 25 Dexamethasone 23 Bendamustine Hydrochloride 22 Antilymphocyte Serum 22 ibrutinib 21 Gemcitabine 21 Whole-Body Irradiation 19 Vincristine 18 Tacrolimus 16 Methylprednisolone 16 pembrolizumab 15 Doxorubicin 15 Brentuximab Vedotin 15 Bortezomib 15 Cord Blood Stem Cell Transplantation 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡